Acute Leukemia French Association

Recent papers from Acute Leukemia French Association

1. Prognostic Impact of FLT3 ‐ ITD Allelic Ratio in AML Patients Treated With High‐Dose Anthracycline and a FLT3 InhibitorAmerican Journal of Hematology · 2026
2. PERK orchestrates an endoplasmic reticulum stress alternative splicing program via CLK1/SRSF1Nature Communications · 2026
3. CEBP and ZEB2 alterations define three distinct subtypes of B‐cell acute lymphoblastic leukemiaHemaSphere · 2026
4. Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohortBlood Cancer Journal · 2026
5. Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapyBlood · 2026
6. Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST StudyBlood · 2026
7. High frequency of CD95 ⁺ / CD45RA ⁻ regulatory T cells defines an immunosuppressive profile associated with MDS progressionBritish Journal of Haematology · 2026
8. Predisposition to ALL and Solid Tumors Rather Than Bone Marrow Failure in FANCM -Associated Fanconi AnemiaJCO Precision Oncology · 2026
9. Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?Leukemia · 2026
10. Homeodomain-driven oncogenic diversion to a TCRγδ phenotype in T-cell Acute Lymphoblastic LeukemiaBlood · 2026
11. Metabolic and epigenetic interplay in HSPC specification: A balance between extrinsic and intrinsic cuesiScience · 2026
12. Integrated analysis of post-transcriptional regulations reveals insights into acute myeloid leukemiaCommunications Biology · 2025
13. Impact of midostaurin in younger AML patients intensively treated with high-dose anthracyclineBlood · 2025
14. Allogeneic hematopoietic stem cell transplantation in adult with acute lymphoblastic leukemia: evolving indications and modalities in shifting landscapeLeukemia & lymphoma/Leukemia and lymphoma · 2025
15. FLT3-ITD measurable residual disease from the QuANTUM-First trialBlood Advances · 2025
16. Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AMLEMBO Molecular Medicine · 2025
17. Impaired cytotoxic function and exhausted phenotype of natural killer cells in VEXAS syndromeBlood · 2025
18. Asciminib for relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemiaBlood Advances · 2025
19. Modeling mesenchymal stromal cell support to hematopoiesis within a novel 3D artificial marrow organoid systemScientific Reports · 2025
20. Intermediate-Dose Cytarabine as Postinduction AML TherapyNEJM Evidence · 2025